Scientists from Chulalongkorn University are studying a new treatment for breast cancer called CAR T-cell therapy. They have created CAR T-cells that target a specific antigen called mucin-1 (MUC1) that is present on breast cancer cells. They compared two different signaling domains, CD28 and 41BB, to see which was better at activating the CAR T-cells. They found that the CAR T-cells with the 41BB signaling domain were better at killing cancer cells and producing inflammatory molecules. They also showed that these CAR T-cells were effective against both breast cancer cell lines and primary breast cancer cells in the laboratory. This study provides evidence for the potential of CAR T-cell therapy targeting MUC1 in breast cancer treatment, and suggests that the 41BB signaling domain could be a better option for activating the CAR T-cells.
เงินทุน
This research was funded by the Center of Excellence on Medical Biotechnology (CEMB), the S&T Postgraduate Education and Research Development Office (PERDO), the Commission on Higher Education (CHE), Thailand, and the Chulalongkorn Academic Advancement in to its Second Century (CUAASC) Project.
กระดาษต้นฉบับ
ชื่อบทความต้นฉบับ: An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment
วารสาร: J Immunol Res
ดอย: 10.1155/2022/2449373